Safety, Tolerability, and Pharmacokinetics of VH4004280 and VH4011499 in Healthy Adults

Phase 1, randomised, double-blind trial of VH-4004280 and VH4011499 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of Participants with Adverse Events as per Severity at 56 weeks, Absolute Values and Change from Baseline in Liver Chemistry Parameters at 56 weeks and 5 more. Started Aug 2023; status: completed.